Presentations & Publications


Anti-Tumor Therapeutic Effects in Mice Treated With Listeria Monocytogenes (Lm)-LLO Immunotherapy In Combination with anti–PD-L1

AACR, April 21, 2015


AACR 2015 Reception Presentation with Late Breaking Poster

AACR, April 19, 2015


Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+ FoxP3- and CD8+ T cells

Published in Cancer Immunology Research, May 28, 2014


Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment

Published in the Journal of Immunotherapy, November 2013


ADXS11-001 LM-LLO Immunotherapy Targeting HPV-E7: Preliminary Safety and Survival Data From a Phase 2 Study in Indian Women With Recurrent/Refractory Cervical Cancer

Published in the Journal for Immunotherapy of Cancer, November 2013


Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

Published in the Journal for ImmunoTherapy of Cancer, August 29, 2013


Listeria monocytogenes-Derived Listeriolysin O Has Pathogen Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability

Published in Clinical and Vaccine Immunology, January 2013


Lm-LLO-Based Immunotherapies and HPV-Associated Disease

Published in Hindawi Publishing Corporation Journal of Oncology, October 2012


The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

Published in Vaccine, May 3, 2009


Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

Published in Vaccine, September 26, 2008


Two Listeria monocytogenes Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16

Published in the Journal of Immunology, September 2001